Northfield Labs Reports Verified Data From Troubled Phase III PolyHeme Study

“Exceeding the noninferiority endpoint by a small margin” in the study should not keep the product out of the broad emergency trauma setting, CEO Gould tells “The Pink Sheet” DAILY.